Loading clinical trials...
Loading clinical trials...
Open Label, Phase III Safety, Efficacy, and Pharmacokinetic Study of NABI-IGIV 10% [Immune Globulin Intravenous (Human), 10%] in Subjects With Primary Immune Deficiency Disorders (PIDD)
Conditions
Interventions
Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]
Locations
17
United States
University of Alabama
Birmingham, Alabama, United States
Precision Trials LLC
Phoenix, Arizona, United States
Children's Hospital of Los Angeles
Los Angeles, California, United States
1st Allergy and Clinical Resaerch center
Centennial, Colorado, United States
Allergy Associates of the Palm Beaches
North Palm Beach, Florida, United States
Marietta Pulmonary Medicine
Marietta, Georgia, United States
Start Date
September 1, 2007
Primary Completion Date
July 1, 2009
Completion Date
July 1, 2009
Last Updated
July 30, 2021
Lead Sponsor
ADMA Biologics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions